Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. Based in Holon.
Compugen: sales sharply up (+58.3%), net income up (+4.8%), operating income down (−6.7%).
- Sales sharply upFirst nine months 2026
Revenue: $9M, vs. $5M a year earlier, i.e. +58.3%.
- Net income upFirst nine months 2026
Net income: $−20M, vs. $−22M a year earlier, i.e. +4.8%.
- Operating income downFirst nine months 2026
Operating income: $−26M, vs. $−25M a year earlier, i.e. −6.7%.
What the market pays, vs. the sector
This company's valuation multiples history is being built day by day from now on.
P/E calculated on net income (trailing 12 months: last fiscal year + 2026 year-to-date − same period a year earlier). Sector median: companies in the — group tracked here. Prices: Yahoo Finance; market cap cross-checked with the Tel Aviv Stock Exchange for Israeli stocks. These ratios describe a price, not a value: none of them says whether the share is expensive or cheap.
Follow earnings · WhatsApp group TA-125Details ▾
Every report from a TA-125 company, analyzed the same day: key figures and year-on-year change, analysis in brief, share price reaction. One daily summary during earnings season.
Join the TA-125 groupDetailed figures and history
Financial summary
| 9 months 2026 | 9 months 2025 | FY 2025 | |
|---|---|---|---|
| Total assets | 130 | 98 | 157 |
| Current assets | 121 | 89 | 148 |
| Non-current assets | 9 | 9 | 9 |
| Equity | 83 | 44 | 103 |
| of which minority interests | 0 | 0 | 0 |
| Current liabilities | 25 | 20 | 23 |
| Non-current liabilities | 22 | 34 | 31 |
| Revenue | 9 | 5 | 73 |
| Gross profit | 2 | −0 | 64 |
| Operating income | −26 | −25 | 31 |
| Pre-tax income | −20 | −21 | 35 |
| Net income | −20 | −22 | 35 |
| Net income (attributable to shareholders) | −20 | −22 | 35 |
| Dividends paid | 0 | 0 | 0 |
| Operating cash flow | 0 | 0 | 32 |
In millions of dollars. The "H1" columns cover the first six months of the year.
Calculated from these figures
| 9 months 2026 | 9 months 2025 | FY 2025 | |
|---|---|---|---|
| Gross margin | 19.5% | −5.2% | 87.3% |
| Operating margin | −306.8% | −455.0% | 43.1% |
| Net margin | −238.1% | −395.8% | 48.6% |
| Current ratio (current assets / current liabilities) | 4,9 x | 4,4 x | 6,6 x |
| Equity / total assets | 64.4% | 44.8% | 65.6% |
The 5-year history, charts and cross-check models are coming for companies listed only in Tel Aviv: each new filing on Maya is kept and enriches the page.
Company overview
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products.
Source: official company profile (Yahoo Finance), summary. Website: cgen.com
- Maya, Tel Aviv Stock Exchange: company page and reports
No dividend paid over the past five years (source: Yahoo Finance).